Treatment of liver metastases, an update on the possibilities and results
Introduction
Colorectal cancer ranks second as a cause of death due to cancer in the Western world. The cumulative lifetime risk is approximately 5%, the incident rate in the Western world 50/100 000 [1]. Liver metastases form the main cause of death in patients with colorectal cancer. Already at the time of detection of the primary tumour, 15–25% of the patients present with liver metastases, another 20% will develop these metastases following treatment of the colorectal primary 2, 3. Without any treatment, the median survival after the detection of liver metastases is approximately 9 months, depending on the extent of the disease at the time of diagnosis [4].
In contrast to many other solid tumours, resection of liver metastases from colorectal origin has been shown to result in long-term survival and even cure. In selected patients with metastatic disease confined to the liver, 5-year survival rates are generally reported between 35 and 40%, depending on the extent of liver involvement 5, 6, 7, 8. Unfortunately, only a minority of patients (10–15%) with liver metastases are considered to be candidates for resection. Most patients have liver metastases that are unresectable. Present challenges in liver surgery are to improve patient selection, to increase resectability rates, and to improve survival by multimodality approaches of treatment.
Section snippets
Patient selection
In the past, several factors were identified that determined clinical outcome after resection of colorectal liver metastases (Table 1). The variables most consistently associated with poor prognosis and tumour recurrence are tumour-positive resection margin of the removed specimen and extrahepatic disease at the time of surgery for liver metastases 6, 7, 8, 9, 10, 11.
Preoperative staging
Preoperative staging of patients with colorectal liver metastases should concentrate on the accurate imaging of the number, size and location of the metastatic lesions within the liver, as well as on the detection of possible extrahepatic disease.
Survival
Resection is still the gold standard for the surgical treatment of colorectal liver metastases. It should be considered in all patients with metastatic disease confined to the liver which can be removed adequately, while leaving enough functional liver reserve.
Many studies over the last two decades have demonstrated long-term survival after liver resection for colorectal liver metastases (Table 2). 5-year survival rates after resection in these series varies from 21 to 50% 6, 7, 8, 9, 10, 11, 35
Local tumour ablation
In many patients with colorectal liver metastases confined to the liver, resection of the metastases can not result in an adequate clearance of all of the tumour tissue from the liver. This may be the case either because of the number of metastatic liver lesions or because of the location of the metastases. Examples are patients with more diffuse bilobar disease or with unresectable recurrence after previous liver surgery. It is in this group of patients with unresectable colorectal liver
Preoperative chemotherapy
Obviously there are many patients with metastastic disease confined to the liver and with a good performance status in whom liver involvement by tumour is either too extensive for surgery or in which tumour lesions are situated at unresectable sites. Several studies have shown that in some of these patients combination chemotherapy may alter unresectable lesions into resectable ones. In these studies, a schedule with 5-FU/LV/oxaliplatin has generally been used 70, 71, 72, 73, 74. In analyses
5-FU/LV
In Europe, until recently the standard first-line treatment in advanced colorectal cancer consisted of 5-fluorouracil (5-FU)-based schedules, in which almost invariably leucovorin (LV) is incorporated 86, 87, 88, 89, 90. Leucovorin enhances the activity of 5-FU which results in response rates of approximately 20% and a median overall survival of approximately 12 months. Many different schedules have been compared in randomised studies, showing differences in response rates and toxicity, but no
References (106)
- et al.
J Factors influencing the natural history of colorectal liver metastases
Lancet
(1994) - et al.
Resection of liver metastases from colorectal cancerthe real impact of the surgical margin
Eur. J. Surg. Oncol.
(1998) - et al.
Resection of hepatic and pulmonary metastases from colorectal cancer
Surg. Oncol.
(1992) - et al.
Hepatic metastases
Radiol. Clin. North Am.
(1998) - et al.
Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases
Am. J. Surg.
(1999) - et al.
Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver
Am. J. Surg.
(1996) - et al.
Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases
Ann. Oncol.
(1998) - et al.
A study of prognostic factors for hepatic resection for colorectal metastases
Am. J. Surg.
(1997) - et al.
Cryoablation of unresectable malignant liver tumors
Am. J. Surg.
(1996) - et al.
Cryosurgical ablation of hepatic tumors
Am. J. Surg.
(1997)
Radiofrequency thermal ablation of hepatic metastases
Eur. J. Ultrasound
Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery
Ann. Oncol.
Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy
Lancet
Atrophy of the liver after occlusion of the bile ducts or portal vein and compensatory hypertrophy of the unoccluded portion its clinical importance
Gastroenterology
Changes in hepatic lobe volume in biliary tract cancer patients after right portal vein embolization
Hepatology
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
Lancet
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
Lancet
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancera multicentre randomised trial
Lancet
Hepatic metastases from colorectal carcinomaimpact of surgical resection on the natural history
Br. J. Surg.
Metastases: incidence, detection nd valuation without histologic confirmation
Surgical resection of colorectal carcinoma metastases to the liver. A pronostic scoring system to improve case selection, based on 1568 patients
Cancer
Resection of the liver for colorectal carcinoma metastasesa multi-institutional study of indications for resection
Surgery
Resection of colorectal liver metastases
World J. Surg.
Liver resection for colorectal metastases
J. Clin. Oncol.
Long-term survival following resection of colorectal hepatic metastases
Br. J. Surg.
Hepatic resection for metastatic colorectal cancer results in cure for some patients
Arch. Surg.
Resection of both hepatic and pulmonary metastases in patients with colorectal cancinoma
Cancer
Surgery for colorectal cancer metastases to the liveroptimising the results of treatment
Surg. Clin. North Am.
Hepatic lymph node involvement in resected cases of liver metasases from colorectal cancer
Dis. Colon Rectum
Peri-operative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma
Ann. Surg.
Results of extensive surgery for liver metastases in colorectal carcinoma
Br. J. Surg.
Clinical score for predicting recurrence after hepatic resection for metastatic colorectal canceranalysis of 1001 consecutive cases
Ann. Surg.
Detection of hepatic metastases in patients with carcinomacomparative sensitivities of sonography, CT, and MR imaging
Am J Roentgenol
Accuracy of intra-operative ultrasonography in diagnosing liver metastases from colorectal cancerevaluation with post-operative follow-up results
World J. Surg.
Role of staging laparoscopy in the treatment of hepatic malignancy
Am. J. Surg.
Selection of patients for resection of colorectal metastases to the liver using diagnostic laparoscopy and laparoscopic ultrasonography
Ann. Surg.
False positive CT portographycorrelation with pathologic findings
Am. J. Roentgenol.
Evaluation of bening vs malignant hepatic lesions with positron emission tomography
Arch. Surg.
Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer
Ann. Surg.
Additional value of whole-body positron emission tomography with fluorine-18–2-fluoro-deoxy-D-glucose in recurrent colorectal cancer
J. Clin. Oncol.
A combined PET/CT scanner for clinical oncology
J. Nucl. Med.
The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver
Arch. Surg.
Hepatic resection for colorectal liver metastases. Influence on survival of preoperative factors and surgery for recurrence in 80 patients
Ann. Surg.
Hepatic resections for colorectal metastases in The Netherlands
Cancer
One hundred patients with hepatic metastases from colorectal cancer treated by resectionanalysis of prognostic determinants
Br. J. Surg.
Experience in hepatic resection for metastatic colorectal canceranalysis of clinical and pathologic risk factors
Surgery
Resection of liver metastases of colorectal carcinoma
World J. Surg.
Cited by (229)
Analysis of therapeutic effect and influencing factors of radiofrequency ablation for colorectal cancer liver metastases
2022, Chinese Journal of Radiology (China)